Details of the Drug

General Information of Drug (ID: DMGOVHA)

Drug Name
Cenobamate
Synonyms
Xcopri; UNII-P85X70RZWS; 913088-80-9; YKP3089; YKP-3089; P85X70RZWS; [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] Carbamate; (R)-1-(2-chlorophenyl)-2-(2H-tetrazol-2-yl)ethyl carbamate; Cenobamate [INN]; Xcopri (TN); YKP-3089 Cenobamate; Cenobamate (USAN/INN); Cenobamate [USAN:INN]; SCHEMBL1682643; CHEMBL3989949; GTPL10773; EX-A3604; 2H-Tetrazole-2-ethanol, alpha-(2-chlorophenyl)-, 2-carbamate, (alphaR)-; Carbamic acid (R)-(+)-1-(2-chlorophenyl)-2-(2H-tetrazol-2-yl)ethyl ester; DB06119; 2H-Tetrazole-2-ethanol, alpha-(2-chlorophenyl)-, carbamate (ester), (alphaR)-; HY-17607; CS-0014686; D11150; Q27286352
Indication
Disease Entry ICD 11 Status REF
Complex partial seizure 8A68.0 Approved [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 267.67
Topological Polar Surface Area (xlogp) 1.5
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 5
Chemical Identifiers
Formula
C10H10ClN5O2
IUPAC Name
[(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate
Canonical SMILES
C1=CC=C(C(=C1)[C@H](CN2N=CN=N2)OC(=O)N)Cl
InChI
InChI=1S/C10H10ClN5O2/c11-8-4-2-1-3-7(8)9(18-10(12)17)5-16-14-6-13-15-16/h1-4,6,9H,5H2,(H2,12,17)/t9-/m0/s1
InChIKey
GFHAXPJGXSQLPT-VIFPVBQESA-N
Cross-matching ID
PubChem CID
11962412
CAS Number
913088-80-9
DrugBank ID
DB06119
TTD ID
DU8CF6
ACDINA ID
D00934

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Voltage-gated sodium channel (Nav) TTIG65Q NOUNIPROTAC Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Cenobamate (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Midostaurin DMI6E0R Moderate Increased metabolism of Cenobamate caused by Midostaurin mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [5]
Gilteritinib DMWQ4MZ Moderate Increased metabolism of Cenobamate caused by Gilteritinib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [6]
Oliceridine DM6MDCF Major Increased metabolism of Cenobamate caused by Oliceridine mediated induction of CYP450 enzyme. Acute pain [MG31] [7]
Ivabradine DM0L594 Moderate Increased metabolism of Cenobamate caused by Ivabradine mediated induction of CYP450 enzyme. Angina pectoris [BA40] [8]
Bedaquiline DM3906J Major Increased metabolism of Cenobamate caused by Bedaquiline mediated induction of CYP450 enzyme. Antimicrobial drug resistance [MG50-MG52] [8]
Erdafitinib DMI782S Major Increased metabolism of Cenobamate caused by Erdafitinib mediated induction of CYP450 enzyme. Bladder cancer [2C94] [9]
Pexidartinib DMS2J0Z Moderate Increased metabolism of Cenobamate caused by Pexidartinib mediated induction of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [10]
HKI-272 DM6QOVN Major Increased metabolism of Cenobamate caused by HKI-272 mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [11]
LY2835219 DM93VBZ Moderate Increased metabolism of Cenobamate caused by LY2835219 mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [12]
Esterified estrogens DM9KZDO Moderate Increased metabolism of Cenobamate caused by Esterified estrogens mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [13]
Tucatinib DMBESUA Moderate Increased metabolism of Cenobamate caused by Tucatinib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [14]
Palbociclib DMD7L94 Moderate Increased metabolism of Cenobamate caused by Palbociclib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [11]
Alpelisib DMEXMYK Moderate Increased metabolism of Cenobamate caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [15]
Cabazitaxel DMPAZHC Moderate Increased metabolism of Cenobamate caused by Cabazitaxel mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [16]
Bosutinib DMTI8YE Major Increased metabolism of Cenobamate caused by Bosutinib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [17]
Macitentan DMP79A1 Moderate Increased metabolism of Cenobamate caused by Macitentan mediated induction of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [18]
PF-04449913 DMSB068 Major Increased metabolism of Cenobamate caused by PF-04449913 mediated induction of CYP450 enzyme. Chronic myelomonocytic leukaemia [2A40] [19]
Intedanib DMSTA36 Moderate Increased metabolism of Cenobamate caused by Intedanib mediated induction of CYP450 enzyme. Colorectal cancer [2B91] [20]
Levonorgestrel DM1DP7T Moderate Increased metabolism of Cenobamate caused by Levonorgestrel mediated induction of CYP450 enzyme. Contraceptive management [QA21] [13]
Osilodrostat DMIJC9X Moderate Increased metabolism of Cenobamate caused by Osilodrostat mediated induction of CYP450 enzyme. Cushing syndrome [5A70] [21]
Ivacaftor DMZC1HS Moderate Increased metabolism of Cenobamate caused by Ivacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [22]
Rivaroxaban DMQMBZ1 Moderate Increased metabolism of Cenobamate caused by Rivaroxaban mediated induction of CYP450 enzyme. Deep vein thrombosis [BD71] [23]
Vilazodone DM4LECQ Moderate Increased metabolism of Cenobamate caused by Vilazodone mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [24]
Vortioxetine DM6F1PU Moderate Increased metabolism of Cenobamate caused by Vortioxetine mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [25]
OPC-34712 DMHG57U Moderate Increased metabolism of Cenobamate caused by OPC-34712 mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [20]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Cenobamate and Esketamine. Depression [6A70-6A7Z] [11]
Polatuzumab vedotin DMF6Y0L Moderate Increased metabolism of Cenobamate caused by Polatuzumab vedotin mediated induction of CYP450 enzyme. Diffuse large B-cell lymphoma [2A81] [20]
Cannabidiol DM0659E Moderate Increased metabolism of Cenobamate caused by Cannabidiol mediated induction of CYP450 enzyme. Epileptic encephalopathy [8A62] [20]
Bay 80-6946 DMLOS5R Moderate Increased metabolism of Cenobamate caused by Bay 80-6946 mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [26]
Tazemetostat DMWP1BH Major Increased metabolism of Cenobamate caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [27]
Mirabegron DMS1GYT Minor Increased metabolism of Cenobamate caused by Mirabegron mediated induction of CYP450 enzyme. Functional bladder disorder [GC50] [28]
Ripretinib DM958QB Moderate Increased metabolism of Cenobamate caused by Ripretinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [11]
Avapritinib DMK2GZX Major Increased metabolism of Cenobamate caused by Avapritinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [8]
Boceprevir DMBSHMF Moderate Increased metabolism of Cenobamate caused by Boceprevir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [29]
Daclatasvir DMSFK9V Major Increased metabolism of Cenobamate caused by Daclatasvir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [8]
MK-1439 DM215WE Major Increased metabolism of Cenobamate caused by MK-1439 mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [8]
Fostemsavir DM50ILT Minor Increased metabolism of Cenobamate caused by Fostemsavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [30]
Cobicistat DM6L4H2 Moderate Increased metabolism of Cenobamate caused by Cobicistat mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [7]
Dolutegravir DMCZGRE Minor Increased metabolism of Cenobamate caused by Dolutegravir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [31]
Elvitegravir DMG9B1U Moderate Increased metabolism of Cenobamate caused by Elvitegravir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [11]
Etravirine DMGV8QU Moderate Decreased metabolism of Cenobamate caused by Etravirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [32]
Rilpivirine DMJ0QOW Moderate Increased metabolism of Cenobamate caused by Rilpivirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [11]
Tolvaptan DMIWFRL Moderate Increased metabolism of Cenobamate caused by Tolvaptan mediated induction of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [8]
Suvorexant DM0E6S3 Moderate Increased metabolism of Cenobamate caused by Suvorexant mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [33]
Tasimelteon DMLOQ1V Moderate Increased metabolism of Cenobamate caused by Tasimelteon mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [34]
Naloxegol DML0B41 Moderate Increased metabolism of Cenobamate caused by Naloxegol mediated induction of CYP450 enzyme. Large intestine motility disorder [DB32] [35]
Pemigatinib DM819JF Major Increased metabolism of Cenobamate caused by Pemigatinib mediated induction of CYP450 enzyme. Liver cancer [2C12] [8]
Crizotinib DM4F29C Moderate Increased metabolism of Cenobamate caused by Crizotinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [36]
Brigatinib DM7W94S Major Increased metabolism of Cenobamate caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [11]
Ceritinib DMB920Z Moderate Increased metabolism of Cenobamate caused by Ceritinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [37]
Lurbinectedin DMEFRTZ Major Decreased metabolism of Cenobamate caused by Lurbinectedin mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [38]
PF-06463922 DMKM7EW Major Increased metabolism of Cenobamate caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [39]
Osimertinib DMRJLAT Moderate Increased metabolism of Cenobamate caused by Osimertinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [40]
Pralsetinib DMWU0I2 Moderate Increased metabolism of Cenobamate caused by Pralsetinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [41]
Selpercatinib DMZR15V Major Increased metabolism of Cenobamate caused by Selpercatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [8]
Artemether DM48QOT Moderate Increased metabolism of Cenobamate caused by Artemether mediated induction of CYP450 enzyme. Malaria [1F40-1F45] [11]
Idelalisib DM602WT Moderate Increased metabolism of Cenobamate caused by Idelalisib mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [42]
GDC-0199 DMH0QKA Major Increased metabolism of Cenobamate caused by GDC-0199 mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [43]
IPI-145 DMWA24P Moderate Increased metabolism of Cenobamate caused by IPI-145 mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [44]
Acalabrutinib DM7GCVW Moderate Increased metabolism of Cenobamate caused by Acalabrutinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [45]
Ibrutinib DMHZCPO Moderate Increased metabolism of Cenobamate caused by Ibrutinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [46]
Ponatinib DMYGJQO Moderate Increased metabolism of Cenobamate caused by Ponatinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [11]
Vemurafenib DM62UG5 Moderate Increased metabolism of Cenobamate caused by Vemurafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [47]
Selumetinib DMC7W6R Major Increased metabolism of Cenobamate caused by Selumetinib mediated induction of CYP450 enzyme. Melanoma [2C30] [48]
LGX818 DMNQXV8 Major Increased metabolism of Cenobamate caused by LGX818 mediated induction of CYP450 enzyme. Melanoma [2C30] [49]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Cenobamate and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [50]
Ubrogepant DM749I3 Moderate Increased metabolism of Cenobamate caused by Ubrogepant mediated induction of CYP450 enzyme. Migraine [8A80] [51]
Rimegepant DMHOAUG Major Increased metabolism of Cenobamate caused by Rimegepant mediated induction of CYP450 enzyme. Migraine [8A80] [52]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Cenobamate and Lasmiditan. Migraine [8A80] [53]
Panobinostat DM58WKG Moderate Increased metabolism of Cenobamate caused by Panobinostat mediated induction of CYP450 enzyme. Multiple myeloma [2A83] [54]
Siponimod DM2R86O Major Increased metabolism of Cenobamate caused by Siponimod mediated induction of CYP450 enzyme. Multiple sclerosis [8A40] [11]
Deflazacort DMV0RNS Major Increased metabolism of Cenobamate caused by Deflazacort mediated induction of CYP450 enzyme. Muscular dystrophy [8C70] [8]
Romidepsin DMT5GNL Moderate Increased metabolism of Cenobamate caused by Romidepsin mediated induction of CYP450 enzyme. Mycosis fungoides [2B01] [20]
Fedratinib DM4ZBK6 Major Increased metabolism of Cenobamate caused by Fedratinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [8]
Ruxolitinib DM7Q98D Moderate Increased metabolism of Cenobamate caused by Ruxolitinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [55]
Rolapitant DM8XP26 Moderate Increased metabolism of Cenobamate caused by Rolapitant mediated induction of CYP450 enzyme. Nausea/vomiting [MD90] [56]
Entrectinib DMMPTLH Major Increased metabolism of Cenobamate caused by Entrectinib mediated induction of CYP450 enzyme. Non-small cell lung cancer [2C25] [57]
S-297995 DM26IH8 Moderate Increased metabolism of Cenobamate caused by S-297995 mediated induction of CYP450 enzyme. Opioid use disorder [6C43] [8]
Olaparib DM8QB1D Major Increased metabolism of Cenobamate caused by Olaparib mediated induction of CYP450 enzyme. Ovarian cancer [2C73] [11]
Istradefylline DM20VSK Moderate Increased metabolism of Cenobamate caused by Istradefylline mediated induction of CYP450 enzyme. Parkinsonism [8A00] [58]
Macimorelin DMQYJIR Moderate Increased metabolism of Cenobamate caused by Macimorelin mediated induction of CYP450 enzyme. Pituitary gland disorder [5A60-5A61] [59]
Lefamulin DME6G97 Major Increased metabolism of Cenobamate caused by Lefamulin mediated induction of CYP450 enzyme. Pneumonia [CA40] [60]
Lonafarnib DMGM2Z6 Major Increased metabolism of Cenobamate caused by Lonafarnib mediated induction of CYP450 enzyme. Premature ageing appearance [LD2B] [61]
Enzalutamide DMGL19D Moderate Increased metabolism of Cenobamate caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [62]
Darolutamide DMV7YFT Moderate Increased metabolism of Cenobamate caused by Darolutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [63]
Silodosin DMJSBT6 Moderate Increased metabolism of Cenobamate caused by Silodosin mediated induction of CYP450 enzyme. Prostate hyperplasia [GA90] [11]
Riociguat DMXBLMP Moderate Increased metabolism of Cenobamate caused by Riociguat mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [64]
Axitinib DMGVH6N Major Increased metabolism of Cenobamate caused by Axitinib mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [65]
Temsirolimus DMS104F Moderate Increased metabolism of Cenobamate caused by Temsirolimus mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [11]
Upadacitinib DM32B5U Moderate Increased metabolism of Cenobamate caused by Upadacitinib mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [66]
Tofacitinib DMBS370 Moderate Increased metabolism of Cenobamate caused by Tofacitinib mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [11]
Asenapine DMSQZE2 Moderate Increased metabolism of Cenobamate caused by Asenapine mediated induction of CYP450 enzyme. Schizophrenia [6A20] [20]
Avanafil DM75CXN Moderate Increased metabolism of Cenobamate caused by Avanafil mediated induction of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [67]
Voxelotor DMCS6M5 Major Increased metabolism of Cenobamate caused by Voxelotor mediated induction of CYP450 enzyme. Sickle-cell disorder [3A51] [68]
LDE225 DMM9F25 Major Increased metabolism of Cenobamate caused by LDE225 mediated induction of CYP450 enzyme. Skin cancer [2C30-2C37] [69]
Larotrectinib DM26CQR Moderate Increased metabolism of Cenobamate caused by Larotrectinib mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [11]
Armodafinil DMGB035 Moderate Increased metabolism of Cenobamate caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [70]
LEE011 DMMX75K Moderate Increased metabolism of Cenobamate caused by LEE011 mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [11]
Pitolisant DM8RFNJ Moderate Increased metabolism of Cenobamate caused by Pitolisant mediated induction of CYP450 enzyme. Somnolence [MG42] [20]
Pomalidomide DMTGBAX Moderate Increased metabolism of Cenobamate caused by Pomalidomide mediated induction of CYP450 enzyme. Systemic sclerosis [4A42] [20]
Fostamatinib DM6AUHV Moderate Increased metabolism of Cenobamate caused by Fostamatinib mediated induction of CYP450 enzyme. Thrombocytopenia [3B64] [71]
Apixaban DM89JLN Moderate Increased metabolism of Cenobamate caused by Apixaban mediated induction of CYP450 enzyme. Thrombosis [DB61-GB90] [72]
Brilinta DMBR01X Moderate Increased metabolism of Cenobamate caused by Brilinta mediated induction of CYP450 enzyme. Thrombosis [DB61-GB90] [7]
Cabozantinib DMIYDT4 Moderate Increased metabolism of Cenobamate caused by Cabozantinib mediated induction of CYP450 enzyme. Thyroid cancer [2D10] [73]
Saxagliptin DMGXENV Moderate Increased metabolism of Cenobamate caused by Saxagliptin mediated induction of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [74]
Linagliptin DMWFJTR Moderate Increased metabolism of Cenobamate caused by Linagliptin mediated induction of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [75]
Elagolix DMB2C0E Moderate Increased metabolism of Cenobamate caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [76]
⏷ Show the Full List of 107 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
FD&C blue no. 2 E00446 2723854 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 3350 E00652 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Haematite red E00236 14833 Colorant
Hydrophobic colloidal silica E00285 24261 Anticaking agent; Emulsion stabilizing agent; Glidant; Suspending agent; Viscosity-controlling agent
Cellulose microcrystalline E00698 Not Available Adsorbent; Suspending agent; Diluent
⏷ Show the Full List of 11 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Cenobamate 25 mg tablet 25 mg Tablet Oral
Cenobamate 100 mg tablet 100 mg Tablet Oral
Cenobamate 150 mg tablet 150 mg Tablet Oral
Cenobamate 200 mg tablet 200 mg Tablet Oral
Cenobamate 50 mg tablet 50 mg Tablet Oral
Cenobamate 12.5 mg tablet 12.5 mg Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
2 Effects of cenobamate (YKP3089), a newly developed anti-epileptic drug, on voltage-gated sodium channels in rat hippocampal CA3 neurons. Eur J Pharmacol. 2019 Jul 15;855:175-182.
3 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
4 Clinical pipeline report, company report or official report of Newron Pharmaceuticals.
5 Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
6 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
7 Canadian Pharmacists Association.
8 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
9 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
10 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
11 Cerner Multum, Inc. "Australian Product Information.".
12 Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
13 Baciewicz AM "Oral contraceptive drug interactions." Ther Drug Monit 7 (1985): 26-35. [PMID: 2859674]
14 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
15 Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
16 Product Information. Jevtana (cabazitaxel). sanofi-aventis , Bridgewater, NJ.
17 Product Information. Bosulif (bosutinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
18 Bruderer S, Aanismaa P, Homery MC, et al. "Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist." AAPS J 14 (2012): 68-78. [PMID: 22189899]
19 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
20 Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
21 Product Information. Isturisa (osilodrostat). Recordati Rare Diseases Inc, Lebanon, NJ.
22 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
23 Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
24 Product Information. Viibryd (vilazodone). Trovis Pharmaceuticals LLC, New Haven, CT.
25 Product Information. Brintellix (vortioxetine). Takeda Pharmaceuticals America, Lincolnshire, IL.
26 Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
27 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
28 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
29 Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
30 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
31 Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
32 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
33 Product Information. Belsomra (suvorexant). Merck & Company Inc, Whitehouse Station, NJ.
34 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
35 Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
36 Cerner Multum, Inc. "Canadian Product Information.".
37 Product Information. Zykadia (ceritinib). Novartis Pharmaceuticals, East Hanover, NJ.
38 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
39 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
40 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
41 Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
42 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
43 Product Information. Venclexta (venetoclax). AbbVie US LLC, North Chicago, IL.
44 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
45 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
46 Product Information. Imbruvica (ibrutinib). Pharmacyclics Inc, Sunnyvale, CA.
47 Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
48 Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
49 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
50 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
51 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
52 Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
53 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
54 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
55 Product Information. Jakafi (ruxolitinib). Incyte Corporation, Wilmington, DE.
56 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
57 Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
58 Product Information. Nourianz (istradefylline). Kyowa Kirin, Inc, Bedminster, NJ.
59 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
60 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
61 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
62 Product Information. Xtandi (enzalutamide). Astellas Pharma US, Inc, Deerfield, IL.
63 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
64 Product Information. Adempas (riociguat). Bayer Pharmaceutical Inc, West Haven, CT.
65 Pithavala YK, Tortorici M, Toh M, et al "Effect of rifampin on the pharmacokinetics of axitinib (AG-013736) in Japanese and Caucasian healthy volunteers." Cancer Chemother Pharmacol 65 (2010): 563-70. [PMID: 19603168]
66 Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.
67 Product Information. Stendra (avanafil). Vivus Inc, Mountain View, CA.
68 Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
69 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
70 Product Information. Nuvigil (armodafinil). Cephalon Inc, West Chester, PA.
71 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
72 Product Information. Eliquis (apixaban). Bristol-Myers Squibb Canada Inc, Montreal, IN.
73 Product Information. Cabometyx (cabozantinib). Exelixis Inc, S San Francisco, CA.
74 Product Information. Onglyza (saxagliptin). Bristol-Myers Squibb, Princeton, NJ.
75 Product Information. Tradjenta (linagliptin). Boehringer Ingelheim, Ridgefield, CT.
76 Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.